Related Experiment Video
Updated: Oct 17, 2026
The Lambda Select cII Mutation Detection System
Published on: April 26, 2018
Evaluation of antimutagenic effect of todralazine in cultured lymphocytes
1Wroclaw Medical University, Department of Basic Medical Sciences, 14 Kochanowskiego Str., 51-01 Wroclaw, Poland. kaz@basmed.am.wroc.pl
Abstract:
Todralazine, an antihypertensive drug from the hydrazinophthalazine group, significantly decreased the activities of benzo[a]pyrene and mitomycin C in three short-term genotoxicity tests in human lymphocyte cultures. The thioguanine resistance test, the cytokinesis-blocked micronucleus assay and the sister chromatid exchange test were used to demonstrate the antimutagenicity of todralazine. Todralazine lowered the level of free radicals generated by human granulocytes in vitro in the presence of benzo[a] pyrene and also in the presence of the granulocyte activator and tumor promoter phorbol myristate acetate. These results, together with our previous data obtained in the standard bacterial Ames test, strongly suggest that todralazine is a good antimutagen in vitro and deserves further research on its inhibitory action on mutagenesis and carcinogenesis.
Insights
Todralazine, an antihypertensive drug, demonstrated antimutagenic properties by reducing genotoxicity in human cells. Further research is recommended for its potential in inhibiting mutagenesis and carcinogenesis.
Area of Science:
- Pharmacology
- Toxicology
- Genetics
Background:
- Hydrazinophthalazine antihypertensives may possess properties beyond blood pressure regulation.
- Environmental mutagens and carcinogens pose significant health risks.
- Understanding drug interactions with cellular defense mechanisms is crucial.
Purpose of the Study:
- To investigate the antimutagenic potential of todralazine.
- To evaluate todralazine's effect on benzo[a]pyrene and mitomycin C genotoxicity.
- To assess todralazine's impact on free radical generation in human granulocytes.
Main Methods:
- Human lymphocyte cultures were used for genotoxicity testing.
- Assays included thioguanine resistance, micronucleus assay, and sister chromatid exchange.
- Free radical levels were measured in human granulocytes in vitro.
Main Results:
- Todralazine significantly decreased benzo[a]pyrene and mitomycin C genotoxicity.
- Antimutagenicity was observed across three distinct short-term genotoxicity tests.
- Todralazine reduced free radical generation induced by benzo[a]pyrene and phorbol myristate acetate.
Conclusions:
- Todralazine exhibits significant in vitro antimutagenic activity.
- The drug's ability to reduce free radicals contributes to its antimutagenic effects.
- Todralazine warrants further investigation for its potential role in preventing mutagenesis and carcinogenesis.
